The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys. The supporters have no influence over the production of the content.
Welcome to The Lymphoma Channel
Diffuse large B-cell Lymphoma (DLBCL) is a malignancy of B-cells and is the most common lymphoid malignancy in adults accounting for 30% of lymphoid malignancies.
It represents a heterogenous group of lymphomas involving the lymph nodes or different extranodal sites. Median age at occurrence is around 70 years despite spanning a broad age range.
Disseminated disease is the most common presentation. The CHOP regimen is the usual standard of care but only induces complete responses in 40-50% of elderly patients and overall survival rates of 30%. Since the introduction of Rituximab, a chimeric anti-CD20IgG1 monoclonal antibody, there has been a significant increase in overall survival. When combined with CHOP, responses have been seen in over 90% of patients.